Our goal is to develop a microfluidic system that provides clinically relevant information by adapting modalities to specific patients and to identify treatments with high efficacy against cancer cells and low toxicity to healthy tissue.
DIPGs are deadly pediatric aggressive gliomas occurring in midline structures of the brain with less than 10% of the very young patients surviving 2 years from diagnosis. Despite increased understanding of DIPG biology, there are no effective treatments, with radiotherapy remaining the standard of care despite offering only transient relief.